Filing Details
- Accession Number:
- 0001246360-13-003624
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-07-17 16:21:09
- Reporting Period:
- 2013-07-15
- Filing Date:
- 2013-07-17
- Accepted Time:
- 2013-07-17 16:21:09
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
911326 | Synageva Biopharma Corp | GEVA | Biological Products, (No Disgnostic Substances) (2836) | 561808663 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1532217 | Chris Heberlig | 33 Hayden Ave Lexington MA 02421 | Vice President, Finance | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2013-07-15 | 400 | $1.70 | 400 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2013-07-15 | 247 | $0.95 | 647 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2013-07-15 | 1,877 | $0.95 | 2,524 | No | 4 | M | Direct | |
Common Stock | Disposition | 2013-07-15 | 495 | $49.15 | 2,029 | No | 4 | S | Direct | |
Common Stock | Disposition | 2013-07-16 | 2,029 | $48.26 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2013-07-15 | 400 | $0.00 | 400 | $1.70 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2013-07-15 | 247 | $0.00 | 247 | $0.95 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2013-07-15 | 1,877 | $0.00 | 1,877 | $0.95 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
3,788 | 2021-05-25 | No | 4 | M | Direct | |
0 | 2019-07-01 | No | 4 | M | Direct | |
0 | 2019-07-01 | No | 4 | M | Direct |
Footnotes
- The stock option exercise and sale of shares of common stock ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 19, 2013.
- The stock option granted the reporting person an option to purchase 6,188 Shares. 25% of such Shares vested and became exercisable on 05/25/2012, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter.
- The stock option granted the reporting person an option to purchase 247 Shares. 25% of such Shares vested and became exercisable on 01/16/2010, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter.
- The stock option granted the reporting person an option to purchase 12,377 Shares. 25% of such Shares vested and became exercisable on 07/01/2010, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from $49.01 to $49.22 The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from $48.00 to $48.96 The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.